Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on August 24, 2009. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with continued listing standards.
Key Financial Metrics
- Stockholders' Equity: Approximately $8.2 million as of June 30, 2009 (based on the Form 10-Q).
- Listing Requirement: $10 million minimum stockholders' equity required by Nasdaq Marketplace Rule 5450(b)(1)(A).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes
The company is currently non-compliant with the Nasdaq Global Market's minimum stockholders' equity requirement. The reported equity of $8.2 million falls short of the $10 million threshold. This deficiency was identified through a review of the quarterly report for the period ended June 30, 2009.
Outlook, Risks, and Management Commentary
- Compliance Plan: The company intends to submit a plan to Nasdaq within 15 calendar days to regain compliance.
- Delisting Risk: There is no assurance that Nasdaq will accept the proposed plan. If rejected, the company faces delisting from the Nasdaq Global Market.
- Contingencies: If delisted, the company may apply for listing on the Nasdaq Capital Market (subject to meeting those requirements) or appeal the decision to a Nasdaq Listing Qualifications Panel. Securities would remain listed pending an appeal decision.
Investor Verification Checklist
- Verify the company's current stockholders' equity status and any capital raise activities intended to meet the $10 million threshold.
- Confirm whether the compliance plan has been submitted to Nasdaq and the status of Nasdaq's review.
- Monitor for any official notice of delisting or acceptance of the compliance plan.
- Review the full Form 10-Q for the period ended June 30, 2009, for detailed financial context not included in this 8-K.